Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Albireo Pharma
Albireo Pharma
(ALBO)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Bylvay
Odevixibat
2021-07-16
2031-2041
Pruritus
,
Intrahepatic cholestasis
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Odevixibat
liver diseases
,
healthy volunteers/patients
,
biliary liver cirrhosis
,
liver cirrhosis
,
fibrosis
,
pruritus
,
cholestasis
,
intrahepatic cholestasis
,
alagille syndrome
,
syndrome
,
biliary atresia
,
pregnancy rate
Elobixibat
non-alcoholic fatty liver disease
,
liver diseases
,
fatty liver
,
dyslipidemias
,
constipation
,
colonoscopy
Insulin
duchenne muscular dystrophy
,
muscular dystrophies
,
growth disorders
,
failure to thrive
,
laron syndrome
,
syndrome
,
dwarfism
,
igg deficiency
,
insulin resistance
,
acromegaly
Viaject
duchenne muscular dystrophy
,
muscular dystrophies
,
growth disorders
,
failure to thrive
,
laron syndrome
,
syndrome
,
dwarfism
,
igg deficiency
,
insulin resistance
,
acromegaly
Lyspro
diabetes mellitus
,
type 1 diabetes mellitus
,
type 2 diabetes mellitus
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use